Understanding Illumina Stock Symbol and Performance

Illumina's stock symbol is ILMN, and it's listed on the NASDAQ stock exchange.

ILMN is a leading developer of next-generation sequencing (NGS) technology, which has revolutionized the field of genomics.

The company's stock price has been on a steady rise since its IPO in 1999, with some fluctuations along the way.

As of my knowledge cutoff, the stock price of ILMN is around $500 per share, but please note that this information may not be up to date.

Expand your knowledge: History of Stock Price Symbol Svm

The Illumina stock has had a tumultuous year, with a 29.51% decline in value from 2024 to 2025. This is evident in the historical annual stock price data, where the average stock price for 2025 is $125.13, a significant drop from the previous year.

The stock's performance can be broken down into various time frames, with the 1-year return standing at -28.67%, significantly underperforming the S&P index's 1-year return of 18.21%. Over the 5-year period, the Illumina stock has seen a decline of 67.33%, whereas the S&P has experienced a 5-year return of 80.16%.

Here's a summary of the Illumina stock's performance over the past 25 years:

The highest price the stock has reached in the past 25 years was $510.20 in August 2021, while the lowest price was $1.64 in 2002.

Illumina's stock performance has been quite volatile over the past year. The company's share price has experienced significant fluctuations, with a notable decline in 2025.

The average daily trading volume has been relatively high, with 773,522 shares traded daily in 2025. This is a significant increase from the 600,353 shares traded daily in 2024.

Looking at the financial year 2025, the share price started at $104.19 and peaked at $156.66. However, it closed at $93.92, indicating a decline of -10.03% (-9.63%) from the starting price.

The biggest decline in share price was observed in FY2024, where the price dropped by -82.28% (-44.08%) from $186.66 to $104.38.

Here's a summary of the share price performance for the past two years:

Illumina's stock has been a solid performer, with a 5-year annualized return of 23.1%, outpacing the S&P 500's 14.1% return.

The company's strong financials are a key driver of its success, with a net income margin of 23.8% and a debt-to-equity ratio of 0.04 as of 2022.

Investors may also want to consider Illumina's growing presence in the genomics market, with a 2022 revenue of $4.7 billion, a 14% increase from the previous year.

Illumina's focus on innovation and R&D has led to the development of new products and technologies, such as the NovaSeq 6000, which has been a game-changer for the company's revenue growth.

Silicon Valley is making a big bet on healthcare, and if you're interested in personalized medicine and precision oncology, you should take a closer look at these top stock ideas.

The Fools have revealed three stock ideas that are worth considering.

These stock ideas are focused on personalized medicine and precision oncology, two areas that are likely to see significant growth in the healthcare industry.

Analysts are optimistic about one of these stocks, with an average rating of "Buy" from 18 analysts.

This stock is expected to see a significant increase in price, with a 12-month forecast of $158.11, which is an increase of 68.27% from the latest price.

Illumina, Inc. is one of the companies that has recently reported better-than-expected results for its fourth quarter.

This could be a sign of good things to come for the company, and for investors who have a stake in it.

You might like: Change Healthcare Stock Symbol

Gilead Sciences is a giant biotech company that's been making waves in the industry. It's known for its innovative treatments for various diseases, including HIV and hepatitis C.

The company has a strong track record of developing and commercializing new medicines, with a focus on viral infections and cancer. Gilead Sciences has a market capitalization of over $100 billion, which is a testament to its size and influence.

Gilead Sciences has a diverse portfolio of products, including its flagship HIV treatment, Truvada. This medication has been a game-changer for people living with HIV, and it's been a major contributor to the company's success.

Investors are drawn to Gilead Sciences because of its steady stream of revenue from its established products, as well as its promising pipeline of new treatments. The company has a reputation for being a solid long-term investment, with a strong balance sheet and a history of delivering on its promises.

Readers also liked: New Relic Stock Symbol

Gilead Sciences is also known for its commitment to research and development, with a focus on discovering new treatments for some of the world's most pressing diseases. This commitment to innovation is a key factor in the company's success, and it's likely to continue driving growth in the years to come.

Illumina's stock symbol is ILMN.

ILMN is a leading developer of next-generation sequencing (NGS) and microarray technologies.

Illumina's stock is listed on the NASDAQ stock exchange.

As of the latest data, Illumina's market capitalization is over $100 billion.

ILMN has seen significant growth in recent years, with a compound annual growth rate (CAGR) of over 20%.

For another approach, see: Stock Symbol B

Illumina, Inc. has been a publicly traded company for over 25 years, with its stock symbol being ILMN. The company's stock price has seen its fair share of fluctuations over the years.

The highest recorded stock price for ILMN was $132.94 on January 1, 2025. This is a significant milestone for the company, indicating a strong start to the year.

ILMN's stock price has also experienced significant drops, with the lowest recorded price being $93.51 on February 22, 2025. This drop represents a decline of 3.92% from the previous day's closing price.

Here's a breakdown of the top 5 highest and lowest recorded stock prices for ILMN:

The average daily movement for ILMN's stock price in February 2025 was -2.45%, indicating a decline in the company's stock value over the period.

In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion.

The company's losses were a significant -$1.22 billion, which is 5.34% more than in 2023.

Illumina's stock price has been experiencing some volatility, with a new 52-week low of 92.24 reached on February 24, 2025.

On February 20, 2025, the stock price moved over +1.10% to 104.13, a notable increase.

Here are some key statistics about Illumina's stock:

The stock's trading volume has exceeded the daily average by +15.01% on February 20, 2025.

Illumina's new HiSeq X Ten system can sequence 18 human genomes in a single day, a 10-fold increase from its previous model. This means researchers can analyze more data in less time.

The system's high-throughput sequencing capabilities also enable the study of complex diseases, such as cancer, by analyzing large amounts of genetic data.

Illumina's technology has the potential to revolutionize the field of multiomic research by providing a more comprehensive understanding of the relationships between genes, proteins, and other molecules.

The company's new NovaSeq 6000 system can sequence 6 human genomes in a single day, making it an ideal choice for large-scale genomic studies.

This new technology has the potential to accelerate the discovery of new treatments and therapies for various diseases.